(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

Novo Nordisk A/S (NVO) tumbled 22% Tuesday - The company attributed its lowered guidance in part to persistent use of ...

Novo Nordisk’s shares plunged more than a fifth on Tuesday, wiping more than €60bn from its value, after it slashed sales and profit forecasts for the year amid competition from US copycat weight-loss ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

In their zeal to "Make America Healthy Again," top Trump administration officials depict patients and the doctors who treat ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than ...